Retinitis pigmentosa drug fails to meet primary endpoint in phase 3 trial

R-Tech Ueno halted the phase 3 study of its eye drop treatment for retinitis pigmentosa, unoprostone, because it failed to demonstrate improved retinal sensitivity.

Though the 52-week, multicenter, randomized, double-masked  trial failed to show a significant change in mean retinal sensitivity compared with placebo, treated eyes did demonstrate improved visual acuity compared to eyes in the placebo group. Additionally, the VFQ-25 scores improved significantly in the treatment group.

Based on these results, R-Tech Ueno cancelled the subsequent open trial study investigating drug safety.